Summit Therapeutics plc (SMMT): Price and Financial Metrics


Summit Therapeutics plc (SMMT)

Today's Latest Price: $3.27 USD

0.05 (-1.51%)

Updated Oct 30 4:00pm

Add SMMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SMMT Stock Summary

  • The ratio of debt to operating expenses for Summit Therapeutics plc is higher than it is for about only 0.42% of US stocks.
  • With a year-over-year growth in debt of -100%, Summit Therapeutics plc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for Summit Therapeutics plc comes in at 1,893.29%, a number that bests 99.56% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Summit Therapeutics plc, a group of peers worth examining would be VYGR, ANAB, CRBP, CARA, and NVAX.
  • Visit SMMT's SEC page to see the company's official filings. To visit the company's web site, go to www.summitplc.com.

SMMT Stock Price Chart Interactive Chart >

Price chart for SMMT

SMMT Price/Volume Stats

Current price $3.27 52-week high $5.49
Prev. close $3.32 52-week low $1.18
Day low $3.25 Volume 51,600
Day high $3.43 Avg. volume 112,036
50-day MA $3.42 Dividend yield N/A
200-day MA $3.02 Market Cap 219.85M

Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Therapeutics +3.8% as Zanganeh reports 7.8% stake

Summit Therapeutics (SMMT) is up 3.8% after-hours after an SEC filing shows a 7.8% stake taken by Maky Zanganeh. That comes via Zanganeh, her revocable trust, and the irrevocable trust of Shaun Zanganeh. The aggregate amount of shares beneficially owned amounts to 5.330,258. (Each trust holds about 2.104M shares, and...

Seeking Alpha | September 28, 2020

Summit Therapeutics +3.8% as Zanganeh reports 7.8?% stake

Summit Therapeutics (SMMT) is up 3.8% after hours after an SEC filing shows a 7.8% stake taken by Maky Zanganeh. That comes via Zanganeh, her revocable trust, and the irrevocable trust of Shaun Zanganeh. The aggregate amount of shares beneficially owned amounts to 5.330,258. (Each trust holds about 2.104M shares,...

Seeking Alpha | September 28, 2020

Summit Announces Intention to Redomicile its Holding Company to the United States

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA,.

Yahoo | July 16, 2020

Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge,.

Yahoo | July 13, 2020

Summit Appoints Michael Donaldson as Chief Financial Officer

Summit Therapeutics plc (SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corporate finance. “Michael joins us at an exciting time in Summit’s growth with our ongoing Phase 3 clinical trials of our precision antibiotic candidate, ridinilazole, and the potential to bring a superior product to patients with C. difficile infection,” said Mr. Bob Duggan, Executive Chairman and Chief Executive Officer of Summit.

Yahoo | June 8, 2020

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo -2.53%
3-mo -9.67%
6-mo 9.73%
1-year 92.35%
3-year -66.90%
5-year -66.87%
YTD 104.38%
2019 39.13%
2018 -89.62%
2017 29.44%
2016 -25.57%
2015 N/A

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7628 seconds.